跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 73 条关于
“Pluvicto (Lu177PSMA)”
全部
73
临床试验
9
药物
1
机构
0
资讯
63
2个月前
Carilion Clinic and FBRI Expand Theranostics Clinical Trials, Positioning Southwest Virginia as a Hub for Targeted Radiopharmaceutical Cancer Therapies
2年前
Pluvicto Demonstrates Significant Radiographic Progression-Free Survival Benefit in PSMA-Positive mCRPC
去年
FDA Expands Pluvicto Approval for Earlier Treatment of Metastatic Prostate Cancer
去年
Alberta Expands Public Access to Pluvicto Radioligand Therapy for Advanced Prostate Cancer
去年
Quebec Expands Public Reimbursement of Pluvicto Radioligand Therapy for Advanced Prostate Cancer
去年
Canadian Negotiations Stall for Novartis' Pluvicto, Leaving Prostate Cancer Patients in Limbo
去年
Actinium Pharmaceuticals Unveils ATNM-400: A Breakthrough Non-PSMA Targeted Radiotherapy for Prostate Cancer
去年
Janux Therapeutics' JANX007 Shows Promising Activity in Metastatic Castration-Resistant Prostate Cancer
2年前
Eli Lilly's Lutetium Zadavotide Guraxetan Shows Promise in Metastatic Castration-Resistant Prostate Cancer
去年
CellBion's Lu-177-DGUL Shows Promise in Metastatic Prostate Cancer Treatment
第 1 页,共 7 页
上一页
下一页